Latest News
|
14 March 2013
0 Likes 
A new untitled letter sent by the US Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP) claims that a brochure for Photocure ASA's bladder cancer detection solution
Read More...
Latest News
|
28 February 2013
0 Likes
The US Food and Drug Administration (FDA) has sent an untitled letter to ParaPRO, a start-up pharmaceutical company whose products focus on the treatment of head lice, saying the company's
Read More...
Latest News
|
22 February 2013
0 Likes
Ophthalmic products manufacturer Alcon Research has been hit with an untitled letter by the US Food and Drug Administration (FDA) regarding its Pataday allergy eye drops, which regulators claim were
Read More...
Latest News
|
14 February 2013
0 Likes
A new untitled letter sent by US regulators to an Internet domain hosting company alleges that the company marketed an unapproved diagnostic test capable of testing for HIV, thereby violating federal
Read More...
Latest News
|
15 October 2012
0 Likes
The US Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP) has issued an untitled letter to Genentech over marketing materials used to promote its drug Tarceva
Read More...
Latest News
|
2 October 2012
0 Likes
An untitled letter sent to manufacturer Endo Pharmaceuticals by the US Food and Drug Administration (FDA) accuses the company of promoting Vantas, a subcutaneous implant used as a palliative treatment
Read More...
Latest News
|
24 July 2012
0 Likes
The US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion(OPDP) has sent an untitled letter to New Jersey-based Validus Pharmaceuticals for alleged deficiencies related to a
Read More...
Latest News
|
18 July 2012
0 Likes
Pharmaceutical manufacturer Britsol-Myers Squibb was the recipient of an Untitled Letter from the US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) regarding
Read More...
Latest News
|
9 July 2012
0 Likes
The US Food and Drug Administration (FDA) sent two untitled warning letters to pharmaceutical companies in as many days in June, warning two companies regarding alleged infractions contained within
Read More...
Latest News
|
6 July 2012
0 Likes
US regulators have sent pharmaceutical manufacturer Valeant Pharmaceuticals an untitled letter after finding a promotion for its Huntington’s disease-treatment drug Xenazine omits “material facts,”
Read More...